Insider Selling: IDEXX Laboratories, Inc. (IDXX) Director Sells 2,974 Shares of Stock
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Daniel M. Junius sold 2,974 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $190.06, for a total value of $565,238.44. Following the completion of the sale, the director now owns 5,602 shares of the company’s stock, valued at approximately $1,064,716.12. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
IDEXX Laboratories, Inc. (IDXX) opened at $185.77 on Friday. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80. The company has a market capitalization of $16,184.84, a P/E ratio of 58.79, a price-to-earnings-growth ratio of 2.28 and a beta of 0.58. IDEXX Laboratories, Inc. has a 12 month low of $145.24 and a 12 month high of $198.73.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million for the quarter, compared to analysts’ expectations of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The business’s quarterly revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.58 EPS. equities analysts predict that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current fiscal year.
A number of analysts recently weighed in on IDXX shares. Piper Jaffray Companies started coverage on IDEXX Laboratories in a research report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 target price for the company. BidaskClub downgraded IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Bank of America lifted their price target on IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. Aegis reaffirmed a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Finally, Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. IDEXX Laboratories has a consensus rating of “Buy” and a consensus price target of $194.00.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: IDEXX Laboratories, Inc. (IDXX) Director Sells 2,974 Shares of Stock” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/insider-selling-idexx-laboratories-inc-idxx-director-sells-2974-shares-of-stock/1906790.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.